Phibro Animal Health Q1 sales rise on mineral nutrition demand
PAHC•Phibro Animal Health's fiscal first-quarter net sales rose 6% year over year to $386.8 million, while adjusted diluted EPS increased 8%. The company maintained fiscal 2027 guidance, including sales of $1.55 billion to $1.60 billion and adjusted diluted EPS of $3.41 to $3.59.
1. Quarterly results
Phibro Animal Health reported fiscal first-quarter net sales of $386.8 million, up 6% year over year. Net income was $29.5 million and adjusted EBITDA was $64.3 million; adjusted diluted EPS increased 8% year over year.
2. Sales drivers and outlook
The company said higher demand and prices in Mineral Nutrition, along with increased demand for Performance Products, drove growth. Increased demand for MFAs in North America and Asia and higher ethanol processing aids sales offset lower virginiamycin sales in Brazil. Phibro maintained fiscal 2027 guidance of $1.55 billion to $1.60 billion in net sales, $258 million to $268 million in adjusted EBITDA, and $3.41 to $3.59 in adjusted diluted EPS.
